Foslevodopa + foscarbidopa

Unassigned

New Medicines

Parkinson's disease

Information

New molecular entity
AbbVie
AbbVie

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

ABBV-951 is a novel levodopa/carbidopa prodrug which has the potential to be delivered through a minimally invasive subcutaneous infusion and provide therapeutic levels of levodopa.
PD is the second most common neurodegenerative disorder after Alzheimer's disease. It typically develops between the ages of 55 and 65 years and occurs in 1-2% of people over the age of 60 years, rising to 3.5% at age 85-89 years. About 0.3% of the general population is affected, and the prevalence is higher among men than women, with a ratio of 1.5 to 1 [1].
Parkinson's disease
Subcutaneous infusion